HGH 191AA

What is HGH 191AA?#

HGH 191AA is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

Mechanism of Action#

HGH 191AA identity and receptor binding Somatropin (HGH 191AA) is the native 22-kDa, 191–amino-acid human growth hormone that binds the growth hormone receptor (GHR), a class I cytokine receptor present as a preformed homodimer. A single GH molecule engages two receptor subunits asymmetrically via site 1 then site 2, producing a rotational realignment of the extracellular and transmembrane domains that converts parallel helices into a crossover geometry to trigger activation.

JAK2 engagement and activation mechanism GHR lacks intrinsic kinase activity and signals through JAK2 bound to the membrane-proximal Box1 motif. Ligand-induced receptor reorientation separates the lower transmembrane/cytoplasmic juxtamembrane regions, relieving the pseudokinase-mediated inhibition within the JAK2 pair and enabling trans-activation. Activated JAK2 phosphorylates tyrosines on the GHR cytoplasmic tail, creating SH2 docking sites for downstream effectors.

Primary downstream signaling pathways and transcriptional outputs

• JAK–STAT axis: STAT5a/b are the dominant transcriptional mediators; STAT1 and STAT3 can also be engaged. STAT5b occupancy at target loci is central to GH actions in liver, including induction of Igf1, Igfals, and feedback regulators Cish and Socs2.
• MAPK/ERK pathway: GHR/JAK2 phosphorylation recruits Shc and activates Ras→Raf→MEK→ERK, driving immediate-early gene programs (e.g., c-fos, c-jun).
• PI3K/AKT/mTOR pathway: Through IRS and Shc adaptors, GH activates PI3K→AKT→mTOR to support anabolic and metabolic effects and to intersect with insulin signaling.
• Src family kinases: A JAK2-independent branch from the upper cytoplasmic domain contributes to specific genomic/immune-regulatory outputs.

Endocrine and paracrine IGF-1 axis Hepatic STAT5b-driven Igf1 transcription generates circulating IGF-1 that mediates many somatotropic endocrine effects; GH also induces local IGF-1 in tissues such as skeletal muscle for paracrine/autocrine actions. These IGF-1 effects interface with insulin/IGF receptors and their IRS→PI3K and Ras/MAPK signaling.

Direct tissue targets and metabolic actions

• Liver: GH via STAT5 regulates Igf1 and Igfals expression; it modulates lipid metabolism pathways through ERK and PI3K/AKT signaling.
• Muscle: GH signaling supports protein synthesis and insulin sensitivity cross-talk; muscle-specific GHR perturbation impairs glucose uptake and alters IRS1 phosphorylation.
• Adipose: GH enhances lipolysis and alters PI3K signaling (e.g., p85α), contributing to changes in insulin responsiveness.

Receptor internalization, downregulation, and negative regulation

• Internalization/ubiquitination: Ligand-dependent GHR internalization requires a cytoplasmic region encompassing residues ~318–380; phenylalanine 346 is critical for ubiquitination/internalization, and GH promotes receptor ubiquitination and degradation. These processes can be mechanistically distinct from other forms of downregulation (e.g., glucocorticoid- or PMA-induced) mapping to different cytoplasmic regions.
• SOCS-mediated turnover: SOCS2 binds phospho-tyrosines within GHR to block STAT5 docking and recruits an Elongin B/C–Cullin E3 ubiquitin ligase via its SOCS box, promoting receptor ubiquitination and degradation; impaired SOCS2 engagement prolongs GH signaling.
• Negative feedback network: Induced CIS/SOCS proteins, PIAS family, SIRT1, and tyrosine phosphatases (PTP1B, SHP1/2) attenuate JAK2–STAT signaling and fine-tune pathway amplitude/duration. Evidence suggests JAK2 can remain associated upon internalization, supporting potential endosomal signaling.

Hormonal and receptor cross-talk GH signaling intersects with insulin/IGF pathways through IRS adaptors and with steroid hormones; estrogens can modulate hepatic GHR–STAT5 signaling and inhibit GH effects in part via SOCS induction, highlighting endocrine context-dependence of GH responses.

Embedded summary

Overall mechanism HGH 191AA (somatropin) binds a preformed GHR dimer to induce a conformational rotation that activates JAK2 at Box1, launching STAT5-dominant transcriptional programs and parallel MAPK/ERK, PI3K/AKT/mTOR, and Src pathways. Hepatic STAT5b-driven IGF‑1 production propagates endocrine growth and metabolic effects, while local IGF‑1 and direct GH actions mediate paracrine tissue remodeling. Signal termination and receptor turnover are enforced by SOCS-directed ubiquitination, receptor internalization (including an F346-dependent ubiquitination step), PIAS and phosphatases, with pathway tuning via cross-talk from insulin/IGF and steroid hormone signaling networks.

Therapeutic Applications#

Overview artifact

Approved indications

• Adult growth hormone deficiency (AGHD). Multiple randomized controlled trials and meta-analyses support GH replacement increasing lean mass and normalizing IGF‑1, with meta-analytic evidence for improvements in bone mineral density; long-term observational data generally support tolerability with expected class adverse events. However, hard outcomes (mortality, major cardiovascular events) remain insufficiently established, and careful monitoring for edema, arthralgia, carpal tunnel, and insulin resistance is required.
• Pediatric GHD and idiopathic short stature (ISS). Phase 3 randomized trials and network meta-analyses show significant increases in annualized height velocity and height SDS with daily somatropin and comparable efficacy to several long-acting GHs at 52 weeks; safety profiles are broadly consistent with class effects. Longer-term, comparative safety across long-acting formulations and final height outcomes require continued study.
• HIV-associated wasting. Randomized trials in the pre-modern ART era demonstrated increases in lean mass and some exercise work outputs with rhGH. Evidence is supportive for short-term anabolic effects, but trials were relatively small/older and long-term safety in contemporary HIV care is less certain.
• Severe pediatric burns. A large single-center, double-blind RCT (n=205) administering rhGH for 12 months post-discharge showed improved growth, lean body mass, reduced fat percentage, and attenuation of hypermetabolism; dose-dependent bone effects (decreased BMC at highest dose) highlight the need for dose optimization and bone monitoring.

Off-label uses and performance claims

• Healthy elderly/“anti-aging.” A systematic review of randomized trials in healthy older adults (cumulative n≈220; ~107 person-years) found modest increases in lean mass and reduced fat mass but no consistent improvements in VO2max, bone density, lipids, glucose/insulin, or functional outcomes. Adverse events were substantially higher with GH (e.g., soft-tissue edema ~50% vs ~8%; carpal tunnel 19% vs 1%; arthralgias 21% vs 5%; incident impaired glucose/diabetes signals). Authors concluded that anti-aging use is not supported and harms may outweigh modest body-composition changes.
• Athletic performance in healthy adults. Systematic reviews/meta-analyses of placebo-controlled trials (11 RCTs; n≈224–254; mostly ≤12 weeks) found GH increases lean mass and reduces fat mass but provides no meaningful gains in VO2max (MD 0.01 L/min, 95% CI −0.11 to 0.13) or muscle strength (relative change ≈ −0.02). One small trial reported improved anaerobic capacity; several studies showed higher exercising lactate, suggesting possible endurance impairment. Adverse effects included edema, arthralgia, and carpal tunnel; lean-mass gains likely reflect fluid retention rather than true hypertrophy.

Key limitations and evidence gaps

• For approved indications: While efficacy on intermediary endpoints (IGF‑1, lean mass, growth velocity, BMD) is supported, data on long-term hard outcomes (fractures in adults, cardiovascular/mortality in AGHD) are incomplete. Comparative long-term safety among long-acting GH formulations is still limited.
• For HIV wasting: Trials are older and small; relevance in the modern ART era and long-term cardiometabolic/oncologic safety require updated studies.
• For severe burns: Single-center RCT with dose stratification reduces per-arm power; bone-related signals at higher doses warrant replication and longer follow-up.
• For anti-aging and performance: The evidence base consists of small, short-duration RCTs, with heterogeneous outcomes and limited functional endpoints; DEXA cannot reliably distinguish fluid from true lean mass, risking overestimation of anabolic effect. Long-term safety and real-world regimens (e.g., co-use with androgens) are untested.

Common criticisms

• Anti-aging claims: Lack of durable functional benefits or morbidity/mortality improvements juxtaposed with higher adverse event rates; frequent need for dose reductions; potential for insulin resistance and new-onset diabetes; methodological limitations in early positive studies.
• Performance enhancement: No robust strength or aerobic capacity gains despite body-composition changes; increased lactate and extracellular water suggest physiological changes that may impair endurance and inflate lean mass estimates; small, short trials limit generalizability.

Conclusions

• Strongest evidence supports somatropin for medically indicated GH deficiency (adult and pediatric), with additional supportive RCTs in pediatric severe burns and historical support in HIV wasting. Safety requires monitoring for class-typical adverse effects. By contrast, in healthy aging and athletic performance, randomized evidence shows modest body-composition effects without meaningful functional or performance benefits and with higher adverse events, underpinning critical consensus against off-label anti-aging/performance use.

Research Evidence Quality#

Objective. We appraised the quality and extent of the evidence base for HGH 191AA (somatropin; recombinant human growth hormone), separating approved indications from off-label uses, and identified limitations, gaps, and recurrent criticisms.

Evidence Gaps and Limitations#

The current evidence base for HGH 191AA consists primarily of preclinical studies. Key limitations include:

• No completed randomized controlled trials in humans
• Most data derived from animal models, limiting direct translatability
• Publication bias may favor positive results
• Long-term safety data in humans is not available
• Optimal dosing for human applications has not been established

Key Research Findings#

Effect of growth hormone treatment on the adult height of children with chronic renal failure, published in N Engl J Med (Haffner D et al., 2000; PMID: 11006368):

• The study showed treated children reached mean final adult height of 1.6 +/- 1.2 SD below normal vs 2.1 +/- 1.2 SD in controls
• The study demonstrated of GH treated children reached final adult height within normal range of 65%

Related Reading#

• HGH 191AA research studies and evidence
• HGH 191AA dosing protocols
• HGH 191AA side effects profile
• IGF-1 LR3 research guide
• MGF research guide